Joseph Tucci

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Henry G. Bone, David Hosking, Jean‐Pierre Devogelaer et al. · New England Journal of Medicine · 2004 · 1.4K citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +13

Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities

Lynn M. Boyden, Murim Choi, Keith A. Choate et al. · Nature · 2012 · 633 citations

Life Sciences, Genetics, Molecular Genetics +11

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

Joseph Tucci, Richard P. Tonino, Ronald Emkey et al. · The American Journal of Medicine · 1996 · 222 citations

Medicine, Endocrinology, Bone Metabolism +10

Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21

Traci A. Mansfield, David B. Simon, Zvi Farfel et al. · Nature Genetics · 1997 · 213 citations

Life Sciences, Genetics, Molecular Genetics +8

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Ethel S. Siris, Robert S. Weinstein, Roy D. Altman et al. · The Journal of Clinical Endocrinology & Metabolism · 1996 · 210 citations · Full text

Medicine, Oral Medicine, Bone Augmentation +16